Arachidonate Derivatives as Endogenous Cannabinoid Substances

  • Daniele Piomelli
Part of the Molecular Biology Intelligence Unit book series (MBIU)


Until 1992, most researchers working on the metabolism of arachidonic acid in the central nervous system were convinced that the brain mobilized and transformed this fatty acid basically as did all other tissues, producing the more or less expected array of bioactive eicosanoids which we have encountered in the preceding chapter. This simple view was radically challenged, however, by a report appeared in the December 18, 1992 issue of Science magazine. The report, originating in the laboratory of Raphael Mechoulam at the Hebrew University in Jerusalem, described the isolation and chemical identification of a bioactive substance present in brain, whose pharmacological properties are basically un-distinguishable from those of Δ9-tetrahydrocannabinol—the psychoactive principle of cannabis.1


Arachidonic Acid Calcium Wave Methyl Arachidonate Fatty Acid Ethanolamides Nabinoid Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Devane WA, Hanus L, Breuer A., Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the can-nabinoid receptor. Science 1992; 258:1946–1949.PubMedCrossRefGoogle Scholar
  2. 2.
    Mechoulam R. The pharmacohistory of cannabis sativa. In: Mechoulam R, ed. Cannabinoids as Therapeutic Agents. Boca Raton: CRC Press 1986; 1–16.Google Scholar
  3. 3.
    Piomelli D. Breve ma veridica storia della canapa indiana. Rome: Stampa Alternativa 1995 (in Italian).Google Scholar
  4. 4.
    Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86:1646–1647.CrossRefGoogle Scholar
  5. 5.
    Dewey WL. Cannabinoid pharmacology. Pharmacological Reviews 1986; 38:151–178.PubMedGoogle Scholar
  6. 6.
    Howlett AC, Qualy JM, Khachaturian LL. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. J Pharmacol Experim Therap 1985; 29:307–313.Google Scholar
  7. 7.
    Howlett AC, Bidaut-Russel M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci 1990; 13:420–423.PubMedCrossRefGoogle Scholar
  8. 8.
    Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TL Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561–564.PubMedCrossRefGoogle Scholar
  9. 9.
    Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA. Cannabinoid agonists stimulate both receptor-dependent and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Molecular Pharmacol 1992; 42:838–845.Google Scholar
  10. 10.
    Henry DJ, Chavkin C. Activation of inward-rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci Letters 1995; 186:91–94.CrossRefGoogle Scholar
  11. 11.
    Mackie K, Hille B. Cannabinoid inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 89: 3825–3829.Google Scholar
  12. 12.
    Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly-rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain can-nabinoid receptors. J Neurosci 1995; 15:6552–6561.PubMedGoogle Scholar
  13. 13.
    Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232:54–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Matsuda LA, Bonner TI, Lolait SJ. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 1993; 327:535–550.PubMedCrossRefGoogle Scholar
  15. 15.
    Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KR. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11:563–582.PubMedGoogle Scholar
  16. 16.
    Evans FJ. Cannabinoids: the separation of central from peripheral effects on a structural basis. Planta Medica 1991; 57:S60–S67.CrossRefGoogle Scholar
  17. 17.
    Hollister LE. Health aspects of cannabis. Pharmacol Reviews 1986; 38:1–20.Google Scholar
  18. 18.
    Iversen LL. Medical uses of marijuana? Nature 1993; 365:12–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptors for cannabinoids. Nature 1993; 265:61–65.CrossRefGoogle Scholar
  20. 20.
    Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Letters 1995; 375:143–147.PubMedCrossRefGoogle Scholar
  21. 21.
    Evans DM, Johnson RM, Howlett AC. Ca2+-dependent release from rat brain of cannabinoid receptor binding activity. J Neurochem 1992; 58:780–782.PubMedCrossRefGoogle Scholar
  22. 22.
    Evans DM, Lake JT, Johnson RM, Howlett AC. Endogenous cannabinoid receptor binding activity released from rat brain slices by depolarization. J Pharmacol Experim Therap 1994; 268: 1271–1277.Google Scholar
  23. 23.
    Mechoulam R, Hanus L, Martin BR. Search for endogenous li-gands of the cannabinoid receptor. Biochem Pharmacol 1994; 48:1537–1544.PubMedCrossRefGoogle Scholar
  24. 24.
    Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993; 231:313–314.PubMedCrossRefGoogle Scholar
  25. 25.
    Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 1995; 92:3376–3380.PubMedCrossRefGoogle Scholar
  26. 26.
    Venance L, Piomelli D, Glowinski J, Giaume C. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 1995; 276:590–592.CrossRefGoogle Scholar
  27. 27.
    Duffy S, Mac Vicar B. Adrenergic calcium signaling in astrocyte networks within the hippocampal slice. J Neurosci 1995; 15: 5535–5550.PubMedGoogle Scholar
  28. 28.
    Sontheimer H. Glial influences on neuronal signaling. The Neuro-scientist 1995; 1:123–126.Google Scholar
  29. 29.
    Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372:686–691.PubMedCrossRefGoogle Scholar
  30. 30.
    Bachur NR, Masek K, Melmon KL, Udenfriend S. Fatty acid amides of ethanolamine in mammalian tissues. J Biol Chem 1965; 240:1019–1024.PubMedGoogle Scholar
  31. 31.
    Schmid HHO, Schmid PC, Natarajan V. N-acylated glycero-phospholipids and their derivatives. Prog Lipid Res 1990; 29:1–43.PubMedCrossRefGoogle Scholar
  32. 32.
    Natarajan V, Schmid PC, Reddy PV, Schmid HHO. Catabolism of N-acyl-ethanolamine phospholipids by dog brain preparations. J Neurochem 1984; 42:1613–1619.PubMedCrossRefGoogle Scholar
  33. 33a.
    Natarajan V, Schmid PC, Reddy PV, Zuzarte-Agustin ML, Schmid HHO. Biosynthesis of N-acyl-ethanolamine phospholipids by dog brain preparations. J Neurochem 1983; 41:1303–1312.PubMedCrossRefGoogle Scholar
  34. 33b.
    Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci 1996; 16:3934–3942.PubMedGoogle Scholar
  35. 34.
    Cadas H, Schinelli S, Piomelli D. Membrane localization of N-acylphosphatidylethanolamine in central neurons: studies with exogenous phospholipases. J Lipid Mediators 1996; in press.Google Scholar
  36. 35.
    Sugiura T, Kondo S, Sukagawa A, Tonegawa T, Nakane S, Yamashita A, Waku Z. Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis: involvement of Ca2+-de-pendent transacylase and phosphodiesterase activities. Biochem Biophys Res Commun 1996; 218:113–117.PubMedCrossRefGoogle Scholar
  37. 36.
    Desarnaud F, Cadas H, Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem 1995; 270:6030–6035.PubMedCrossRefGoogle Scholar
  38. 37.
    Hillard C, Wilkinson DM, Edgemond WS, Campbell WB. Characterization of the kinetics and distribution of N-arachido-noylethanolamine (anandamide) hydrolysis by rat brain. Biochim Biophys Acta 1995; 1257:249–256.PubMedCrossRefGoogle Scholar
  39. 38.
    Ueda N, Kurahashi Y, Yamamoto S, Tokunaga T. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J Biol Chem 1995; 270:23823–23827.PubMedCrossRefGoogle Scholar
  40. 39.
    Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993; 46:791–796.PubMedCrossRefGoogle Scholar
  41. 40.
    Devane WA, Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc Natl Acad Sci USA 1994; 91:6698–6701.PubMedCrossRefGoogle Scholar
  42. 41.
    Kruszka KK, Gross RW. The ATP- and CoA-independent synthesis of arachidonoylethanolamide. J Biol Chem 1995; 269: 14345–143348.Google Scholar
  43. 42.
    Ueda N et al. Lipoxygenase-catalyzed oxygenation of arachidonoylethanolamide, a cannabinoir receptor agonist. Biochim Biophys Acta 1995; 1254:127–134.PubMedCrossRefGoogle Scholar
  44. 43.
    Hampson AJ, Hill WAG, Zan-Phillips M, Makriyannis A, Leung E, Eglen RM, Bornheim LM. Anandamide hydroxylation by brain lipoxygenase: metabolite structures and potencies at the cannabinoid receptor. Biochim Biophys Acta 1995; 1259:173–179.PubMedCrossRefGoogle Scholar
  45. 44.
    Hanus L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 1993; 36:3032–3034.PubMedCrossRefGoogle Scholar
  46. 45.
    Pertwee R, Griffin G, Hanus L, Mechoulam R. Effects of of two endogenous fatty acid ethanolamides on mouse vas deferentia. Eur J Pharmacol 1994; 259:115–120.PubMedCrossRefGoogle Scholar
  47. 46.
    Mechoulam R, et al. Identification of an endogenous 2-mono-glyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50:83–90.PubMedCrossRefGoogle Scholar
  48. 47.
    Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku Z. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215:89–97.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1996

Authors and Affiliations

  • Daniele Piomelli
    • 1
  1. 1.The Neurosciences InstituteSan DiegoUSA

Personalised recommendations